Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Aphton Corp. (NasdaqNM:APHT)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Options | Reports
Recent Events
Aug 15Earnings Announcement
Location
444 Brickell Avenue, Suite 51-507
Miami, FL 33131
Phone: (305) 374-7338
Fax: (305) 374-7615
Employees (last reported count): 25
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 39%
·Institutional: 32% (52% of float)
(81 institutions)
·Net Inst. Buying: 583.0K shares (+10.20%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Aphton Corporation is a biopharmaceutical company in late-stage clinical trials for four cancer indications. Aphton is developing products using its vaccine-like technology to block hormones that play key roles in cancer and other disorders of the gastrointestinal and reproductive systems. The Company is initially targeting large cancer markets where there are no standards of care available. The Company's lead product, an anti-gastrin immunogen, is in two separate Phase III clinical trials for pancreatic cancer in the United States and Europe; in a pivotal trial for chemo-refractory colorectal cancer; and in a Phase II study in gastric (stomach) cancer. Aphton has strategic alliances with Aventis Pasteur, GlaxoSmithKline, Schering Plough Animal Health, and the World Health Organization (WHO).
More from Market Guide: Expanded Business Description

Financial Summary
APHT is a biopharmaceutical company developing products using its innovative vaccine-like technology for neutralizing hormones that participate in gastrointestinal system and reproductive system cancer and non-cancer diseases; and the prevention of pregnancy. For the comparable five months ended 6/30/01, revenues were $0. Net loss rose 80% to $9.9 million. Results reflect the absence of contract revenues, and increases in research and development expenses.
More from Market Guide: Significant Developments

Officers
FY2000 Compensation
PayExer

Philip Gevas, 67
Chairman, CEO and Pres
$400K--  
William Hasler, 59
Vice Chairman and Co-CEO
180K$111K
Dov Michaeli, Ph.D., 62
Sr. VP, Director of Medical Science and CMO
210K2.2M
Douglas Eayrs
VP-Fin.
--  --  
Donald Henderson
VP and Managing Director, finance and administration
--  --  
Dollar amounts are as of 31-Jan-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:APHTAs of 31-Aug-2001
Price and Volume
52-Week Low
on 20-Mar-2001
$12.125
Recent Price$13.26 
52-Week High
on 25-Sep-2000
$30.75 
Beta0.79 
Daily Volume (3-month avg)56.4K
Daily Volume (10-day avg)73.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-55.4%
52-Week Change
relative to S&P500
-40.2%
Share-Related Items
Market Capitalization$214.8M
Shares Outstanding16.2M
Float9.90M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$0.08 
Earnings (ttm)-$1.20 
Earnings (mrq)-$0.40 
SalesN/A 
Cash (mrq*)$0.58 
Valuation Ratios
Price/Book (mrq*)174.92 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
Sales (ttm)$0 
EBITDA (ttm*)-$18.7M
Income available to common (ttm)-$19.4M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJan 31
Most recent quarter
(fully updated)
30-June-2001
Most recent quarter
(flash earnings)
31-July-2001
Management Effectiveness
Return on Assets (ttm)-67.55%
Return on Equity (ttm)-156.55%
Financial Strength
Current Ratio (mrq*)1.50 
Debt/Equity (mrq*)0 
Total Cash (mrq)$9.39M
Short Interest
As of 8-Aug-2001
Shares Short691.0K
Percent of Float7.0%
Shares Short
(Prior Month)
721.0K
Short Ratio27.64 
Daily Volume25.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 31-July-2001, except mrq*/ttm* items as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.